Verona Pharma plc (NASDAQ:VRNA – Get Free Report) CFO Mark W. Hahn sold 141,360 shares of the company’s stock in a transaction dated Thursday, October 24th. The stock was sold at an average price of $4.38, for a total transaction of $619,156.80. Following the completion of the transaction, the chief financial officer now owns 13,672,560 shares of the company’s stock, valued at approximately $59,885,812.80. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Verona Pharma Stock Performance
Shares of NASDAQ VRNA opened at $33.86 on Monday. Verona Pharma plc has a 1 year low of $11.39 and a 1 year high of $35.62. The firm has a market cap of $2.71 billion, a P/E ratio of -43.97 and a beta of 0.44. The stock has a fifty day moving average price of $29.96 and a two-hundred day moving average price of $21.50. The company has a debt-to-equity ratio of 0.72, a quick ratio of 8.61 and a current ratio of 8.61.
Verona Pharma (NASDAQ:VRNA – Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.53). During the same quarter last year, the company earned ($0.11) earnings per share. Research analysts forecast that Verona Pharma plc will post -2.07 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Check Out Our Latest Report on Verona Pharma
Hedge Funds Weigh In On Verona Pharma
Several large investors have recently made changes to their positions in the business. NEA Management Company LLC raised its holdings in shares of Verona Pharma by 9.3% in the 2nd quarter. NEA Management Company LLC now owns 5,584,753 shares of the company’s stock worth $80,756,000 after purchasing an additional 476,190 shares in the last quarter. Frazier Life Sciences Management L.P. increased its holdings in shares of Verona Pharma by 10.0% in the second quarter. Frazier Life Sciences Management L.P. now owns 3,314,349 shares of the company’s stock valued at $47,925,000 after buying an additional 300,000 shares in the last quarter. Maverick Capital Ltd. increased its holdings in shares of Verona Pharma by 74.2% in the second quarter. Maverick Capital Ltd. now owns 3,092,807 shares of the company’s stock valued at $44,722,000 after buying an additional 1,316,998 shares in the last quarter. Janus Henderson Group PLC lifted its position in shares of Verona Pharma by 12.7% during the 1st quarter. Janus Henderson Group PLC now owns 2,031,994 shares of the company’s stock valued at $32,657,000 after acquiring an additional 228,633 shares during the last quarter. Finally, Jennison Associates LLC boosted its stake in shares of Verona Pharma by 0.5% during the 1st quarter. Jennison Associates LLC now owns 1,593,833 shares of the company’s stock worth $25,645,000 after acquiring an additional 8,448 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.
About Verona Pharma
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
Featured Stories
- Five stocks we like better than Verona Pharma
- What are earnings reports?
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- What is a buyback in stocks? A comprehensive guide for investors
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.